|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, risk factors, and screening. Semin Liver Dis.
25:143–154. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rossi L, Zoratto F, Papa A, Iodice F,
Minozzi M, Frati L and Tomao S: Current approach in the treatment
of hepatocellular carcinoma. World J Gastrointest Oncol. 2:348–359.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson PJ: Hepatocellular carcinoma: Is
current therapy really altering outcome? Gut. 51:459–462. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoshida Y, Toffanin S, Lachenmayer A,
Villanueva A, Minguez B and Llovet JM: Molecular classification and
novel targets in hepatocellular carcinoma: Recent advancements.
Semin Liver Dis. 30:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi-Yanaga F and Sasaguri T: The
Wnt/beta-catenin signaling pathway as a target in drug discovery. J
Pharmacol Sci. 104:293–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chiang DY, Villanueva A, Hoshida Y, Peix
J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M,
et al: Focal gains of VEGFA and molecular classification of
hepatocellular carcinoma. Cancer Res. 68:6779–6788. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boyault S, Rickman DS, de Reyniès A,
Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti
J, Franco D, et al: Transcriptome classification of HCC is related
to gene alterations and to new therapeutic targets. Hepatology.
45:42–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tubaro A, Del Negro P, Ragazzi E, Zampiron
S and Loggia R Della: Anti-inflammatory and peripheral analgesic
activity of esculetin in vivo. Pharmacol Res Commun. 20 Suppl
5:S83–S85. 1988. View Article : Google Scholar
|
|
12
|
Kaneko T, Tahara S and Takabayashi F:
Suppression of lipid hydroperoxide-induced oxidative damage to
cellular DNA by esculetin. Biol Pharm Bull. 26:840–844. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee SY, Lim TG, Chen H, Jung SK, Lee HJ,
Lee MH, Kim DJ, Shin A, Lee KW, Bode AM, et al: Esculetin
suppresses proliferation of human colon cancer cells by directly
targeting beta-catenin. Cancer Prev Res (Phila). 6:1356–1364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim AD, Han X, Piao MJ, Hewage SR, Hyun
CL, Cho SJ and Hyun JW: Esculetin induces death of human colon
cancer cells via the reactive oxygen species-mediated mitochondrial
apoptosis pathway. Environ Toxicol Pharmacol. 39:982–989. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Lu ML, Dai HL, Zhang SP, Wang HX
and Wei N: Esculetin, a coumarin derivative, exerts in vitro and in
vivo antiproliferative activity against hepatocellular carcinoma by
initiating a mitochondrial-dependent apoptosis pathway. Braz J Med
Biol Res. 48:245–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rubinfeld B, Albert I, Porfiri E, Fiol C,
Munemitsu S and Polakis P: Binding of GSK3beta to the
APC-beta-catenin complex and regulation of complex assembly.
Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee HH, Uen YH, Tian YF, Sun CS, Sheu MJ,
Kuo HT, Koay LB, Lin CY, Tzeng CC, Cheng CJ, et al: Wnt-1 protein
as a prognostic biomarker for hepatitis b-related and hepatitis
C-related hepatocellular carcinoma after surgery. Cancer Epidemiol
Biomarkers Prev. 18:1562–1569. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahashi-Yanaga F and Kahn M: Targeting
Wnt signaling: Can we safely eradicate cancer stem cells? Clin
Cancer Res. 16:3153–3162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas
A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev
Genet. 5:691–701. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nesbit CE, Tersak JM and Prochownik EV:
MYC oncogenes and human neoplastic disease. Oncogene. 18:3004–3016.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Diehl JA: Cycling to cancer with cyclin
D1. Cancer Biol Ther. 1:226–231. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Landis MW, Pawlyk BS, Li T, Sicinski P and
Hinds PW: Cyclin D1-dependent kinase activity in murine development
and mammary tumorigenesis. Cancer Cell. 9:13–22. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee YM and Sicinski P: Targeting cyclins
and cyclin-dependent kinases in cancer: Lessons from mice, hopes
for therapeutic applications in human. Cell Cycle. 5:2110–2114.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Z, Wang C, Prendergast GC and Pestell
RG: Cyclin D1 functions in cell migration. Cell Cycle. 5:2440–2442.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moon RT: Wnt/beta-catenin pathway. Sci
STKE. 2005.cm1PubMed/NCBI
|
|
29
|
Haraguchi K, Ohsugi M, Abe Y, Semba K,
Akiyama T and Yamamoto T: Ajuba negatively regulates the Wnt
signaling pathway by promoting GSK-3beta-mediated phosphorylation
of beta-catenin. Oncogene. 27:274–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng XC, Wang XM, Zhang Y, Li J and Shen
ZH: Sulindac induces SMMC-7721 cells apoptosis through inhibiting
Wnt pathway. Fudan Univ J Med Sci. 1–526. 2007.
|
